IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 217 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,792 | -27.7% | 393,776 | +11.8% | 0.08% | -22.2% |
| Q2 2023 | $2,480 | -2.2% | 352,306 | -15.1% | 0.11% | -10.0% |
| Q1 2023 | $2,536 | +1.4% | 415,013 | +6.0% | 0.12% | -13.7% |
| Q4 2022 | $2,501 | -99.9% | 391,393 | +13.9% | 0.14% | -30.2% |
| Q3 2022 | $3,292,000 | +81.0% | 343,673 | +108.5% | 0.20% | +45.3% |
| Q2 2022 | $1,819,000 | +128.5% | 164,805 | +244.9% | 0.14% | +163.5% |
| Q1 2022 | $796,000 | +14.7% | 47,778 | +31.3% | 0.05% | -40.2% |
| Q4 2021 | $694,000 | -16.8% | 36,375 | +7.5% | 0.09% | -21.6% |
| Q3 2021 | $834,000 | +138.3% | 33,838 | +151.6% | 0.11% | -5.9% |
| Q2 2021 | $350,000 | -35.1% | 13,450 | +15.7% | 0.12% | -23.4% |
| Q4 2020 | $539,000 | -36.1% | 11,621 | -62.2% | 0.15% | -46.3% |
| Q2 2020 | $844,000 | -43.8% | 30,757 | -38.7% | 0.29% | -54.7% |
| Q1 2020 | $1,501,000 | +125.7% | 50,149 | +108.9% | 0.63% | +218.1% |
| Q4 2019 | $665,000 | +107.2% | 24,011 | +83.6% | 0.20% | +67.2% |
| Q2 2019 | $321,000 | – | 13,080 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 3,876,600 | $127,618,000 | 11.48% |
| Fairmount Funds Management LLC | 596,890 | $19,650,000 | 8.32% |
| Ghost Tree Capital, LLC | 575,000 | $18,929,000 | 5.47% |
| Perceptive Advisors | 10,085,632 | $332,019,000 | 4.85% |
| Avoro Capital Advisors LLC | 9,536,039 | $313,926,000 | 4.46% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $43,224,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 315,000 | $10,370,000 | 2.82% |
| Orbimed Advisors | 6,645,100 | $218,757,000 | 2.75% |
| QVT Financial LP | 572,971 | $18,862,000 | 2.30% |
| Prosight Management, LP | 120,606 | $3,970,000 | 1.89% |